Daily Briefing
Thursday, March 12, 2026
The Vibe
PULSE agents combine medical literature retrieval with clinical reasoning while pharmaceutical approvals bypass traditional trials entirely — evidence-based AI meets evidence-free drug pathways [1][2]. The contrast exposes healthcare's dual standards for validation.
Research
•PULSE medical reasoning agent integrates domain-tuned LLMs with scientific literature retrieval to support diagnostic decision-making in 82 authentic clinical cases, demonstrating how AI can ground clinical reasoning in published evidence rather than pattern matching alone [1]. The system addresses the reproducibility crisis by forcing models to cite their diagnostic logic.
•Clinical summarization models still introduce unsupported statements in Brief Hospital Course narratives despite alignment training, with new VERI-DPO framework using claim verification to reduce hallucinations while preventing "say-less" degeneration [3]. The work tackles AI's tendency to either fabricate details or omit critical information when generating clinical documentation.
•CBCT interpretation framework addresses the skill gap in oral and maxillofacial radiology by generating structured reports from cone beam CT scans, tackling a domain where high-quality training data remains scarce [4]. The approach could democratize specialized imaging interpretation beyond major medical centers.
•Hybrid knowledge-grounded system for prescription verification combines LLMs with drug interaction databases to create traceable medication safety checks, acknowledging that zero-tolerance domains require different AI architectures than general-purpose applications [5]. Pharmacist verification gets algorithmic backup with full audit trails.
Clinical Practice & Ops
•Epic previews Factory platform for building and orchestrating AI agents at HIMSS26, expanding beyond documentation into clinical workflow automation across multiple EHR modules [6]. The move positions Epic as an AI platform company, not just a records vendor.
•FDA approves leucovorin for ultrarare cerebral folate deficiency without requiring clinical trials, five months after RFK Jr. promoted the drug for autism treatment during White House presentations [2]. The precedent raises questions about evidence standards when patient populations number in the hundreds.
•Vertex seeks expedited FDA approval for povetacicept in IgA nephropathy after Phase 3 success, leveraging the $4.9B acquisition's regulatory pathway for rare kidney disease [7]. The immunology drug targets two pathways simultaneously for maximum nephroprotection.
Industry & Products
•Bristol Myers Squibb gains FDA approval for Sotyktu in psoriatic arthritis, expanding the first-in-class oral TYK2 inhibitor beyond psoriasis into inflammatory joint disease [8]. The dual indication strategy maximizes commercial potential for the novel mechanism.
•Capricor's DMD cell therapy returns to FDA review after previous rejection, with the agency resuming evaluation following submission of additional clinical data [9]. The reversal signals FDA flexibility on rare disease therapies when sponsors provide compelling post-hoc evidence.
Policy & Regulatory
•Primary care practices band together into Independent Physician Associations to boost market power against insurers and hospital systems, fighting to remain financially viable and independent [10]. The consolidation wave now includes small practice defensive mergers.
•Emergency room visits for pediatric dental pain increase as rural dental shortages worsen and anti-fluoride policies gain traction under Trump administration cuts [11]. The convergence creates a perfect storm for preventable emergency care utilization.
Blogs
•PEEM framework evaluates prompt engineering by analyzing both prompts and responses jointly, moving beyond simple accuracy metrics to understand why prompts succeed or fail [12]. The approach gives practitioners actionable guidance for LLM optimization rather than trial-and-error iteration.
The Conversation
•NEJM Group polls clinicians on blood pressure targets in hypertension management — systolic goals below 120 mmHg versus below 140 mmHg — highlighting persistent uncertainty in cardiovascular care despite decades of outcome studies [13]. The debate reflects real-world confusion over intensive versus standard treatment thresholds.
One to Watch
Cosmetic surgery investigation by KFF Health News and NBC prompts national plastic surgeons group to warn patients about safety risks, with calls for tighter standards following scrutiny of surgical chains [14].